1. Home
  2. PGY vs TBPH Comparison

PGY vs TBPH Comparison

Compare PGY & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pagaya Technologies Ltd.

PGY

Pagaya Technologies Ltd.

HOLD

Current Price

$14.17

Market Cap

971.3M

Sector

Finance

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.63

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGY
TBPH
Founded
2016
2013
Country
United States
United States
Employees
518
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
971.3M
824.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
PGY
TBPH
Price
$14.17
$16.63
Analyst Decision
Strong Buy
Buy
Analyst Count
8
6
Target Price
$34.50
$18.40
AVG Volume (30 Days)
2.8M
473.9K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
279.13
EPS
N/A
2.06
Revenue
N/A
$15,386,000.00
Revenue This Year
$14.96
$1.04
Revenue Next Year
$13.97
N/A
P/E Ratio
$13.54
$8.08
Revenue Growth
N/A
N/A
52 Week Low
$8.95
$8.33
52 Week High
$44.99
$21.03

Technical Indicators

Market Signals
Indicator
PGY
TBPH
Relative Strength Index (RSI) 65.77 59.16
Support Level $10.58 $13.41
Resistance Level $25.47 $19.04
Average True Range (ATR) 0.76 0.52
MACD 0.35 0.22
Stochastic Oscillator 98.96 83.84

Price Performance

Historical Comparison
PGY
TBPH

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: